NMN & NAD Metabolism
NAD research | Biomarkers • Metabolism • Healthy Aging
Common names: NMN · nicotinamide mononucleotide · NR · nicotinamide riboside · NAD · NAD+ · NAD metabolism · NAD supplementation
- Evidence searched through
- August 24, 2026
- Last reviewed
- August 24, 2026
- Current version
- 1.0
4V Take
What the research shows.
NMN can raise NAD-related markers in humans, which tells us it is affecting the pathway researchers are trying to target. The bigger question is whether that turns into meaningful benefits for aging, metabolism, muscle or lifespan, and so far the results are mixed. We do not have evidence that NMN slows human aging.
Explore the evidenceResearch Interest
Why are people interested?
Researchers are studying NMN & NAD Metabolism across the approved public questions in this record. Those questions are areas of research interest, not guaranteed outcomes.
Evidence Context
What have researchers looked at?
This approved record brings together the research settings represented in its selected public sources. Evidence settings answer different questions, so human, animal, laboratory, and research-review findings stay distinct.
Current research context
Research stage describes the maturity of the current topic record. Source context describes the evidence settings represented in the selected public sources below; they are not interchangeable.
- Research stage
- Developing
- Selected source context
- Human · Mixed · Research Review
At a Glance
Research snapshot.
- 01Human Research
Growing randomized literature - 02Research Stage
Developing - 03Direct Signal
NAD-related biomarkers - 04Clinical Outcomes
Mixed
Research Pathway
Follow the questions.
Choose a pathway to read its approved 4V Take. Each view stays focused on one question at a time.
4V Take
Oral NMN can increase circulating NAD-related biomarkers in humans.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- oral NMN
Explore the evidence
human synthesis
2026 NAD+ supplementation anti-aging/wellness systematic review.
human direct
Yoshino M et al. Science. 2021.
human synthesis
2026 safety/metabolic meta-analysis.
4V Take
Short-term oral NMN has generally been tolerated in randomized human trials without a clear overall increase in serious adverse events.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- short-term oral NMN
Explore the evidence
human direct
Yoshino M et al. Science. 2021.
human synthesis
2026 safety/metabolic meta-analysis.
human synthesis
2026 NAD+ supplementation anti-aging/wellness systematic review.
4V Take
Broad improvements in fasting glucose, HbA1c, lipids, body weight, or BMI are not consistently demonstrated in meta-analyses.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- oral NMN meta-analyses
Explore the evidence
human synthesis
2026 safety/metabolic meta-analysis.
human direct
Yoshino M et al. Science. 2021.
human synthesis
2026 NAD+ supplementation anti-aging/wellness systematic review.
4V Take
A randomized trial in postmenopausal women with prediabetes found improved muscle insulin sensitivity after NMN.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- postmenopausal women with prediabetes
Explore the evidence
human direct
Yoshino M et al. Science. 2021.
human synthesis
2026 safety/metabolic meta-analysis.
human synthesis
2026 NAD+ supplementation anti-aging/wellness systematic review.
4V Take
Human physical-performance and vascular signals remain heterogeneous and endpoint-specific.
- Evidence bucket
- human clinical
- Research stage
- developing clinical
- Route / format
- human physical and vascular outcomes
Explore the evidence
human direct
Yoshino M et al. Science. 2021.
human synthesis
2026 safety/metabolic meta-analysis.
human synthesis
2026 NAD+ supplementation anti-aging/wellness systematic review.
4V Take
Human evidence does not establish NMN as a proven anti-aging or lifespan-extending intervention.
- Evidence bucket
- mixed
- Research stage
- developing clinical
- Route / format
- human anti-aging outcomes
Explore the evidence
human synthesis
2026 NAD+ supplementation anti-aging/wellness systematic review.
human direct
Yoshino M et al. Science. 2021.
human synthesis
2026 safety/metabolic meta-analysis.
Selected Sources
Explore the evidence.
Open an approved public source to inspect its study context, limitations, and original record where available.
human direct
Yoshino M et al. Science. 2021.
2021 · PMID: 33888596 · peer reviewed
human synthesis
2026 safety/metabolic meta-analysis.
2026 · PMID: 42514320 · peer reviewed
human synthesis
2026 NAD+ supplementation anti-aging/wellness systematic review.
2026 · PMID: 41655607 · peer reviewed
human synthesis
2025 glucose/lipid meta-analysis.
2025 · PMID: 39116016 · peer reviewed
human synthesis
2025 muscle mass/function meta-analysis.
2025 · PMID: 40275690 · peer reviewed
Research Status
Living research, deliberately tracked.
- Evidence searched globally through:
- August 24, 2026
- Last reviewed
- August 24, 2026
- Version
- 1.0
What Changed
Current record.
No later approved public release is available beyond the current topic record.
Evidence Boundaries
What are researchers still working out?
Study settings, measures, and limitations matter. A mechanism does not establish an outcome, animal or laboratory findings do not establish a human benefit, and a small study does not create consensus. Open each selected source for the approved record behind its finding.
Save / Follow
Keep this research close.
Save and Follow remain private account preferences. Following does not activate monitoring or notifications.
Loading member research actions.